Padnarsertib

Drug Overview

Padnarsertib (formerly known by its developmental code KPT-9274 or ATG-019) is an investigational, orally bioavailable, first-in-class small molecule that acts as a dual inhibitor of two distinct targets: p21-activated kinase 4 (PAK4) and nicotinamide phosphoribosyltransferase (NAMPT).

In the clinical landscape of March 2026, padnarsertib represents a novel “dual-lethality” approach to oncology. By simultaneously targeting a signaling kinase (PAK4) and a metabolic enzyme (NAMPT), the drug aims to disrupt both the growth signals and the energy supply of cancer cells. PAK4 is a serine/threonine kinase involved in cell survival and migration, often overexpressed in a variety of solid and hematological malignancies. NAMPT is the rate-limiting enzyme in the NAD+ salvage pathway; since many cancer cells are “addicted” to high levels of NAD+ for DNA repair and metabolism, inhibiting NAMPT effectively starves the tumor of its essential energy currency. Developed by Karyopharm Therapeutics and licensed by Antengene for certain territories, padnarsertib is being evaluated for its ability to overcome resistance in tumors that have failed standard chemotherapy and immunotherapy.

• Generic Name: Padnarsertib.
• Code Names: KPT-9274, ATG-019.
• Drug Class: PAK4/NAMPT Dual Inhibitor; Antineoplastic Agent.
• Mechanism: Allosteric binding to PAK4 causing its degradation, combined with direct inhibition of NAMPT to deplete cellular NAD+ pools.
• Route of Administration: Oral (Tablet).
• FDA Approval Status: Investigational. As of March 2026, padnarsertib is not FDA-approved. It has been evaluated in Phase 1 and Phase 2 clinical trials for advanced solid tumors and certain leukemias.

What Is It and How Does It Work? (Mechanism of Action)

Padnarsertib works by creating a “metabolic and signaling crisis” within the cancer cell.

1. PAK4 Inhibition and Degradation

PAK4 is a member of the p21-activated kinase family that regulates the cytoskeleton and promotes cell cycle progression.

• Allosteric Binding: Unlike many inhibitors that only block an enzyme’s active site, padnarsertib binds allosterically to PAK4.
• Protein Destabilization: This binding causes the PAK4 protein to become unstable and leads to its proteasomal degradation.
• Signal Interruption: Without PAK4, the tumor loses its ability to activate survival pathways like Wnt/β-catenin and mTORC2, leading to growth arrest.

2. NAMPT Inhibition (NAD+ Depletion)

NAMPT is critical for the “salvage pathway” that recycles nicotinamide into NAD+.

• Energy Starvation: By blocking NAMPT, padnarsertib causes a rapid drop in intracellular NAD+ levels.
• Metabolic Collapse: Since NAD+ is required for glycolysis, the TCA cycle, and DNA repair (via PARP), the cancer cell can no longer generate energy or fix genetic damage, leading to autophagic or apoptotic cell death.

Clinical Indications and Research Status (2026)

In 2026, research into padnarsertib focuses on tumors that are known to overexpress both PAK4 and NAMPT:

• Advanced Solid Tumors: This includes heavily pre-treated patients with colorectal cancer, lung cancer, and melanoma. Phase 1/2 trials (such as NCT02702141) have investigated the drug as a monotherapy.
• Clear Cell Renal Cell Carcinoma (ccRCC): Kidney cancer cells are particularly sensitive to NAD+ depletion. Preclinical data has shown that padnarsertib can significantly decrease kidney cancer growth in patient-derived models.
• Triple-Negative Breast Cancer (TNBC): Studies published in 2024–2025 explored the drug’s ability to downregulate the mTORC2 pathway, a common escape route for TNBC.
• B-cell Acute Lymphoblastic Leukemia (B-ALL): Evaluated for its ability to target the specific “metabolic vulnerability” of leukemia cells to NAD+ depletion.
• Combination Strategies: In early 2026, there is active interest in combining padnarsertib with PARP inhibitors (like olaparib). Because NAMPT inhibition lowers the NAD+ that PARP enzymes need to function, the combination may create a “synthetic lethal” effect even in tumors without BRCA mutations.

Dosage and Administration Protocols

As an investigational agent, padnarsertib dosing is strictly controlled within clinical trials to manage the unique metabolic effects of the drug.

Clinical Efficacy and Research Results (2024–2026)

Recent data from the clinical development program have yielded the following insights:

• Target Engagement: 2025 results confirmed that padnarsertib successfully induces PAK4 degradation in patient tumor biopsies, with some patients showing a 70% reduction in protein levels.
• Disease Stabilization: In early-phase trials, roughly 35-40% of patients with refractory solid tumors achieved stable disease (SD), suggesting the drug may be more “cytostatic” (stopping growth) than “cytotoxic” (killing cells) at current doses.
• Biomarker Correlation: Research in 2026 is focusing on whether high baseline levels of NAMPT can predict which patients will experience the most significant NAD+ depletion.

Safety Profile and Side Effects

The side effects of padnarsertib are largely related to its impact on systemic NAD+ levels and its influence on highly active healthy tissues.

Common Side Effects (>25%):

• Gastrointestinal: Nausea, vomiting, and diarrhea.
• Fatigue: A very common report, likely due to the drug’s impact on cellular energy production.
• Decreased Appetite: Often occurring in conjunction with GI issues.

Serious Risks:

• Hematologic Toxicity: Lowered counts of white blood cells (neutropenia), red blood cells (anemia), and platelets (thrombocytopenia).
• Metabolic Changes: Potential for elevations in blood lactate or changes in glucose metabolism.
• Electrolyte Imbalance: Periodic drops in sodium or potassium levels.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, padnarsertib is being used to study “Metabolic Plasticity.” Researchers are investigating how Cancer Stem Cells switch their energy sources when NAMPT is inhibited. In 2026, there is also focus on “Immune-Oncology Synergy,” where scientists are looking at whether depleting NAD+ in the tumor microenvironment can stop T-cell exhaustion, potentially making the tumor more susceptible to checkpoint inhibitors.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Genetic/Protein Screening: Some trials require confirmation of PAK4 or NAMPT overexpression.
• Baseline Metabolic Panel: To establish starting levels for kidney function and electrolytes.

“Do’s and Don’ts” List:

• DO report any “extreme muscle weakness” or “shortness of breath” immediately; these could be signs of systemic NAD+ depletion.
• DO maintain a consistent diet; sudden changes in nutrition can affect how the drug impacts your metabolism.
• DON’T take high doses of Nicotinamide (Vitamin B3) supplements unless directed by your doctor, as these could provide a “workaround” for the NAMPT inhibition and make the drug less effective.
• DON’T ignore persistent diarrhea, which can lead to rapid dehydration and electrolyte imbalances while on this therapy.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Padnarsertib (KPT-9274) is an investigational agent and is not approved by the U.S. FDA for commercial use. Access is restricted exclusively to registered clinical trials. Always consult with a board-certified oncologist or principal investigator regarding your specific diagnosis and clinical trial eligibility.